{"id":"thymosin-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Thymosin-α1 is a naturally occurring 28-amino acid peptide derived from the thymus gland that acts as an immunomodulator. It enhances T-cell differentiation and maturation, increases IL-2 and interferon-gamma production, and promotes both innate and adaptive immune responses. The peptide is thought to work through pattern recognition receptors and may enhance antitumor and antiviral immunity.","oneSentence":"Thymosin-α1 is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic development and activating innate and adaptive immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:33.628Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer immunotherapy (phase 3 development)"},{"name":"Viral infections and immune enhancement"}]},"trialDetails":[{"nctId":"NCT06966687","phase":"NA","title":"Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)","status":"ENROLLING_BY_INVITATION","sponsor":"Nanjing Medical University","startDate":"2025-04-01","conditions":"Aortic Dissection, Aortic Dissection Aneurysm","enrollment":200},{"nctId":"NCT06139419","phase":"PHASE2","title":"The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-25","conditions":"Non-small Cell Lung Cancer","enrollment":114},{"nctId":"NCT05339529","phase":"NA","title":"Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)","status":"RECRUITING","sponsor":"Nanjing Medical University","startDate":"2022-07-01","conditions":"Acute Aortic Syndrome, Aortic Dissection Type a","enrollment":330},{"nctId":"NCT06607926","phase":"NA","title":"Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-15","conditions":"Resectable Non-Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT04963712","phase":"EARLY_PHASE1","title":"Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder","status":"COMPLETED","sponsor":"Shanghai Public Health Clinical Center","startDate":"2021-09-01","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT05487469","phase":"NA","title":"Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2022-07-01","conditions":"Rheumatic Heart Disease, Cardiopulmonary Bypass, Immunotherapy","enrollment":200},{"nctId":"NCT03659578","phase":"PHASE2","title":"Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-08-09","conditions":"Non-small Cell Lung Cancer","enrollment":69},{"nctId":"NCT03663764","phase":"PHASE2","title":"Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-08-13","conditions":"Thymoma and Thymic Carcinoma","enrollment":57},{"nctId":"NCT03082885","phase":"NA","title":"The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-04-10","conditions":"Liver Failure","enrollment":120},{"nctId":"NCT04901104","phase":"","title":"Long-term Prognosis of Patients With Sepsis After Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-07-01","conditions":"Long-term Effects of Thymosin Alpha 1 Treatment","enrollment":900},{"nctId":"NCT02127268","phase":"PHASE3","title":"Thymosin-α1 in Cancer-Related Fatigue","status":"UNKNOWN","sponsor":"Zhigang Zhang","startDate":"2014-04","conditions":"Cancer Related Fatigue, Quality of Life","enrollment":200},{"nctId":"NCT03509688","phase":"NA","title":"The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2014-11","conditions":"Hepatitis","enrollment":312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":315,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zadaxin"],"phase":"phase_3","status":"active","brandName":"Thymosin-α1","genericName":"Thymosin-α1","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Thymosin-α1 is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic development and activating innate and adaptive immunity. Used for Cancer immunotherapy (phase 3 development), Viral infections and immune enhancement.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}